Market News & Trends
Quotient Sciences Acquires UK-Based Contract Development & Manufacturing Organization
Quotient Sciences, the drug development and manufacturing accelerator, recently announced it has acquired Arcinova, the UK-based multiservice contract development and….
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor
Celon Pharma S.A. recently announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in….
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDAr as First-line Treatment for HPV+ Recurrent/Metastatic Head & Neck Cancer
Cue Biopharma, Inc. recently announced the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck's anti-PD-1…
OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines & Therapeutics
OliX Pharmaceuticals, Inc. recently announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of messenger RNA (mRNA) vaccines and…
Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain & Sedation Drug Candidate
Melt Pharmaceuticals, Inc. recently announced results from its MELT Phase 1 study, a comparative bioavailability study with the objective of characterizing the pharmacokinetic parameters of…
uniQure Announces Positive Recommendation From Data Safety Monitoring Board of Phase 1/2 Clinical Trial
uniQure N.V. recently announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase 1/2 clinical trial of AMT-130 for the treatment of Huntington’s…
Hyloris & Purna Female Healthcare Announce Development Partnership
Hyloris Pharmaceuticals SA and Purna Female Healthcare recently announced they have entered into a partnership to develop and commercialize an innovative combination therapy for the…
Emerald Health Pharmaceuticals Demonstrates Potential Disease-Modifying Activity of Novel Product Candidate With Multi-Modal Mechanism of Action in Parkinson’s Disease
Emerald Health Pharmaceuticals Inc. recently published a scientific article in the peer-reviewed journal, Molecular and Cellular Neuroscience, highlighting data supporting the potential of EHP’s drug…
Trizell Signs Development & Manufacturing Agreement With Catalent for Macrophage-Based Advanced Cell Therapy
Catalent recently announced it has signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of…
Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast-Track Designation
Theratechnologies Inc. recently announced the US FDA has granted fast-track designation to TH1902 as a single agent for the treatment of patients with sortilin positive…
Decibel & Catalent Sign Development & Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing
Catalent and Decibel Therapeutics recently announced they have signed an agreement for Catalent to provide Decibel with process and analytical development, and CGMP clinical manufacturing…
Noble Launches Human Factors Engineering Services to Support Product Development and US FDA Approval of Medical Devices & Combination Products
Noble, an Aptar Pharma company and world leader in providing drug delivery training device programs for pharmaceutical companies and original equipment manufacturers, recently announced the launch of Human Factors Plus (HF+), an expanded service to further….
Biogen Announces FDA Approval of PLEGRIDY (Peginterferon Beta-1a) Intramuscular Administration for Multiple Sclerosis
Biogen Inc. recently announced the US FDA has approved a new intramuscular (IM) injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of….
Beroni Acquires Majority Interest in Anti-Cancer Drug Development Company
Beroni Group recently announced it has completed its majority acquisition of the Sydney-based anti-cancer drug development company, PENAO Pty Ltd. As a result of this acquisition….
Albumedix Collaborates With CGT Catapult to Advance Cell & Gene Therapies
Albumedix Ltd. recently announced it has entered into a collaboration agreement with the Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for….
X-Chem Enters Multitarget Oncology Discovery Research Collaboration & License Agreement With Genentech
X-Chem, Inc. recently announced it has entered into a research collaboration and license agreement with Genentech, a member of the Roche Group. The goal of…
Gerresheimer Has Optimized the Test Cartridge & Reagent Block for Ergonomic Handling & Plastic-Suitable Production
Medical technology specialist Gerresheimer has developed the test cartridge and reagent block for a fully automatic blood analyzer that can be used to identify a…
Patent on Improved Particle Size Testing Method Granted to Hovione Will Impact Market
Grants for a patent describing an innovative method to improve particle size analysis methods by laser diffraction have been recently announced by Hovione Technology Ltd,…
GSK & CureVac to Develop Next-Generation mRNA COVID-19 Vaccines
GlaxoSmithKline plc and CureVac N.V. recently announced a new €150-million collaboration, building on their existing relationship, to jointly develop next-generation mRNA vaccines for COVID-19 with…
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia & Cushing’s Disease Advances Into Phase 1 Study
Crinetics Pharmaceuticals, Inc. recently announced that CRN04894, the company’s lead adrenocorticotropic hormone (ACTH) antagonist for the treatment of diseases associated with excess ACTH such as Cushing’s…
